Delivery Order SPE2DE24D0013-SPE2D626F435Z
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded Cepheid Inc. a $21,888.40 firm fixed-price delivery order on December 5, 2025, for COVID-19/Influenza/RSV diagnostic supplies, with completion targeted for December 12, 2025. This delivery order, issued without set-aside designation, represents procurement under the agency's medical supply chain operations and aligns with Cepheid's established role as a primary federal supplier of molecular diagnostic testing solutions. The work will be...
- Cepheid Inc., a Sunnyvale, California-based molecular diagnostics manufacturer, received a delivery order valued at $5,440 on December 1, 2025, from the Defense Logistics Agency Medical Supply Chain for COVID-19, influenza, and respiratory syncytial virus (RSV) diagnostic supplies. This firm fixed-price delivery order, with an ultimate completion date of December 8, 2025, carries no set-aside designation and represents a continuation of Cepheid's established role as a primary federal supplier of...
- The U.S. Defense Logistics Agency, through its Medical Supply Chain division, awarded Cepheid Inc. a delivery order valued at $22,240 on September 9, 2025, for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV). This firm fixed-price delivery order, which has no set-aside designation, is scheduled for completion by September 16, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. Cepheid is a for-profit...
- The Defense Logistics Agency Medical Supply Chain awarded a $9,868.32 firm fixed-price delivery order to Cepheid Inc. on November 5, 2025, for respiratory diagnostic testing supplies related to COVID-19, influenza, and respiratory syncytial virus detection. The delivery order, which carries an ultimate completion date of November 13, 2025, represents a near-term procurement of molecular diagnostic reagents and test kits utilizing Cepheid's GeneXpert diagnostic platform. No set-aside...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $9,104.20 to Cepheid Inc. on December 11, 2025, for respiratory diagnostic testing supplies under contract 4570253151. The delivery order, designated XPCOV2/FLU/RSV-10, calls for firm fixed-price delivery of molecular diagnostic reagents and test cartridges for detecting COVID-19, influenza, and respiratory syncytial virus on the GeneXpert diagnostic platform. The work will be performed at Cepheid's headquarters...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic systems, has been awarded a delivery order valued at $16,381 by the Defense Logistics Agency Medical Supply Chain for COVID-19, influenza, and respiratory syncytial virus (RSV) diagnostic supplies. The delivery order, issued on November 12, 2025, with an ultimate completion date of November 19, 2025, utilizes a firm fixed-price structure with no set-aside designation. This award represents a continuation of...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of advanced molecular diagnostic systems, received a $4,198.65 firm fixed-price delivery order (Contract No. 4569971781) from the Defense Logistics Agency Medical Supply Chain on November 10, 2025, for respiratory pathogen diagnostic supplies related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The delivery order is scheduled for completion by November 18, 2025, and carries no set-aside designation. The award...
- The Defense Logistics Agency Medical Supply Chain awarded Cepheid Inc. a firm fixed-price delivery order valued at $8,160 on October 28, 2025, for diagnostic reagents and test kits related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The delivery order, designated XPCOV2/FLU/RSV-10, carries an ultimate completion date of November 4, 2025, and will be performed at Cepheid's headquarters in Sunnyvale, California. This award utilizes no set-aside designation,...
- The Defense Logistics Agency Medical Supply Chain awarded a $10,550 firm fixed-price delivery order to Cepheid Inc. on November 3, 2025, for the Kit Xpert Xpress COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) plus Molecular Biology diagnostic testing supplies. The delivery order, which will be completed by November 10, 2025, represents a continuation of Cepheid's role as a primary federal supplier of molecular diagnostic solutions. This contract is not subject to any small business...
- The Defense Logistics Agency Medical Supply Chain awarded a $13,600 firm fixed-price delivery order to Cepheid Inc. on November 4, 2025, with an ultimate completion date of November 12, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic testing supplies and reagents for detecting COVID-19, influenza, and respiratory syncytial virus. Cepheid, headquartered in Sunnyvale, California, is a leading federal supplier of advanced molecular diagnostic systems and...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D626F435ZDelivery Order
The Defense Logistics Agency Medical Supply Chain awarded Cepheid Inc. a $10,000 firm fixed-price delivery order on November 24, 2025, for COVID-19, influenza, and respiratory syncytial virus diagnostic supplies. The delivery order, valued at the ceiling amount, is scheduled for completion by December 2, 2025, with performance taking place at Cepheid's headquarters in Sunnyvale, California. This delivery order carries no set-aside designation and represents a continuation of Cepheid's established role as a primary federal supplier of molecular diagnostic solutions and testing kits to the Defense Logistics Agency's Medical Supply Chain organization. Cepheid has demonstrated substantial capacity in delivering molecular diagnostic products and services across federal healthcare agencies, including the Department of Veterans Affairs, Indian Health Service, Defense Health Agency, and U.S. Coast Guard. The company maintains two significant Indefinite Delivery Contracts with the VA totaling over $39.5 million and extending through 2030, which establish the framework for ongoing procurement of diagnostic reagents, test kits, and molecular testing systems. The current delivery order reflects DLA Medical Supply Chain's reliance on Cepheid's GeneXpert diagnostic platform and associated respiratory pathogen testing capabilities to support federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.0k | 11/23/25 |